IL4 and lichen planus: Although the exact mechanism remains unclear, it has been proposed that dupilumab's inhibition of IL-4 and IL-13 may indirectly downregulate IL-6-driven Th2 responses, which are elevated in patients with lichen planus and may contribute to disease persistence [7].